AbCellera Biologics Inc vs United States Natural Gas Fund — how do they compare? AbCellera Biologics Inc trades at $9.02 (market cap $2.85B), while United States Natural Gas Fund trades at $10.13. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| ABCL | UNG | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Commodities - Energy |
52-Week High | $9.76 | $16.90 |
52-Week Low | $2.78 | $9.63 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
UNG trades at $9.74, up 1.14% in the last 24 hours, amid bearish technical signals from moving averages and oscillators. The stock lacks key financial ratio data, but news highlights natural gas futures volatility and comparisons with equity-based ETFs like FCG. Recent articles from WSJ and Reuters (June 2026) note steady trading ranges and record supply-demand forecasts from the EIA, influencing sentiment.
Outlook remains cautious due to technical weakness and commodity price dependence. Risks include geopolitical tensions and weather-driven demand shifts. Opportunities may arise from LNG demand growth, but investors face high volatility without clear fundamental anchors from traditional ratios.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →